COST-EFFECTIVENESS OF LIRAGLUTIDE VERSUS DAPAGLIFLOZIN FOR THE TREATMENT OF PATIENTS WITH TYPE-2 DIABETES MELLITUS IN THE UK

被引：0
|
作者：
Schlueter, M. [1 ]
Vega-Hernandez, G. [2 ]
Wojcik, R. [1 ]
机构：
[1] IMS Hlth, London, England
[2] Novo Nordisk Ltd, Gatwick, England
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.1886
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB56
引用
收藏
页码：A675 / A675
页数：1
相关论文
共 50 条
  • [41] COST-EFFECTIVENESS ANALYSIS OF EXENATIDE ONCE-WEEKLY VERSUS DULAGLUTIDE, LIRAGLUTIDE AND LIXISENATIDE FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS: AN ANALYSIS FROM THE UK NHS PERSPECTIVE
    Charokopou, M.
    Chuang, L.
    Verheggen, B.
    Gibson, D.
    Grandy, S.
    Kartman, B.
    VALUE IN HEALTH, 2015, 18 (07) : A606 - A606
  • [42] THE COST-EFFECTIVENESS OF DAPAGLIFLOZIN IN COMBINATION WITH INSULIN FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN SPAIN
    Sanchez-Covisa, J.
    Capel, M.
    Schmidt, R.
    Charokopou, M.
    Verheggen, B. G.
    VALUE IN HEALTH, 2014, 17 (07) : A350 - A350
  • [43] COST-EFFECTIVENESS OF LIRAGLUTIDE FOR SUBJECTS WITH TYPE 2 DIABETES IN SPAIN
    Ramirz de Arellano, A.
    Hunt, B.
    Mezquita Raya, P.
    Briones, T.
    Perez, A.
    Valentine, W. J.
    VALUE IN HEALTH, 2014, 17 (03) : A249 - A250
  • [44] Cost Effectiveness of Adding Dapagliflozin to Insulin for the Treatment of Type 2 Diabetes Mellitus in the Netherlands
    Heleen G. M. van Haalen
    Marjolein Pompen
    Klas Bergenheim
    Phil McEwan
    Rebecca Townsend
    Marina Roudaut
    Clinical Drug Investigation, 2014, 34 : 135 - 146
  • [45] Cost Effectiveness of Adding Dapagliflozin to Insulin for the Treatment of Type 2 Diabetes Mellitus in the Netherlands
    van Haalen, Heleen G. M.
    Pompen, Marjolein
    Bergenheim, Klas
    McEwan, Phil
    Townsend, Rebecca
    Roudaut, Marina
    CLINICAL DRUG INVESTIGATION, 2014, 34 (02) : 135 - 146
  • [46] The cost-effectiveness of dulaglutide versus insulin glargine for the treatment of type 2 diabetes mellitus in Japan
    Ishii, Hitoshi
    Madin-Warburton, Matthew
    Strizek, Alena
    Thornton-Jones, Lucy
    Suzuki, Shuichi
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (05) : 488 - 496
  • [47] COST-EFFECTIVENESS OF EXENATIDE ONCE WEEKLY VERSUS INSULIN GLARGINE AND LIRAGLUTIDE FOR THE TREATMENT OF TYPE 2 DIABETES IN GREECE
    Tzanetakos, C.
    Bargiota, A.
    Kourlaba, G.
    Maniadakis, N.
    VALUE IN HEALTH, 2016, 19 (07) : A672 - A672
  • [48] EVALUATING THE COST-EFFECTIVENESS OF LIRAGLUTIDE 1.8MG VERSUS LIXISENATIDE 20μG FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN THE SPANISH SETTING
    Kragh, N.
    Ye, E.
    Hunt, B.
    Valentine, W. J.
    VALUE IN HEALTH, 2016, 19 (07) : A673 - A673
  • [49] COST-EFFECTIVENESS OF DULAGLUTIDE, LIRAGLUTIDE, AND GLARGINE IN ADULT PATIENTS WITH DIABETES MELLITUS IN COLOMBIA
    Lasalvia, P.
    Baquero, L.
    Restrepo, P.
    OtaloraOtalora, M.
    Castaneda-CardonaCastaneda-Cardona, C.
    Rosselli, D.
    VALUE IN HEALTH, 2016, 19 (03) : A7 - A7
  • [50] COST-EFFECTIVENESS OF DAPAGLIFLOZIN AS ADD-ON TO METFORMIN FOR THE TREATMENT OF TYPE 2 DIABETES IN GREECE
    Tzanetakos, C.
    Tentolouris, N.
    Kourlaba, G.
    Maniadakis, N.
    VALUE IN HEALTH, 2015, 18 (07) : A606 - A607
12345